Sema4A is upregulated on GC TIL-Bs of HPV+ HNSCC and drives naïve TIL-Bs towards activated and GC phenotypes, which can be one way to complement current CD8+ T-cell-based immunotherapies. Here, SEMA4A is linked to head and neck squamous cell carcinoma.